<DOC>
	<DOC>NCT00960791</DOC>
	<brief_summary>The purpose of the study is to evaluate the absorption, distribution, metabolism and excretion of AZD1656 after administration of a single oral dose of 14C-labelled AZD1656 solution in male Type 2 Diabetes Mellitus patients.</brief_summary>
	<brief_title>Study to Assess the Absorption, Distribution, Metabolism and Excretion of AZD1656 in Type 2 Diabetes Mellitus (T2DM)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Male type II diabetes patients diagnosed for more than 5 years and aged between 35 and 65 years. Subjects treated with metformin alone or metformin and one other oral antidiabetic drug. Subjects should have FPG in the range of 6.0 to 11.0 mmol/L at screening and HbA1c less than 10% (HbA1c value according to international DCCT standard). History of ischemic heart disease, stroke, transient ischemic attack or symptomatic peripheral vascular disease. Renal dysfunction. Use of insulin, glitazones, warfarin and amiodarone within 3 months before enrolment and use of potent CYP450 inhibitors, e.g., ketoconazole and macrolide antibiotics within 14 days before administration of IP.</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Type II diabetes mellitus</keyword>
	<keyword>absorption</keyword>
	<keyword>distribution</keyword>
	<keyword>metabolism</keyword>
	<keyword>excretion</keyword>
	<keyword>14C-labelled</keyword>
</DOC>